1.00
-0.01(-0.99%)
Currency In USD
| Previous Close | 1.01 |
| Open | 1.01 |
| Day High | 1.02 |
| Day Low | 0.98 |
| 52-Week High | 2.19 |
| 52-Week Low | 0.86 |
| Volume | 269,902 |
| Average Volume | 524,656 |
| Market Cap | 145.47M |
| PE | -2.7 |
| EPS | -0.37 |
| Moving Average 50 Days | 1.29 |
| Moving Average 200 Days | 1.51 |
| Change | -0.01 |
If you invested $1000 in Biodesix, Inc. (BDSX) since IPO date, it would be worth $78.06 as of February 05, 2025 at a share price of $1. Whereas If you bought $1000 worth of Biodesix, Inc. (BDSX) shares 3 years ago, it would be worth $285.71 as of February 05, 2025 at a share price of $1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)
GlobeNewswire Inc.
Jan 10, 2025 11:00 AM GMT
Grew full-year revenue to an estimated $71.3 million, an increase of 45%LOUISVILLE, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its preliminary financial results fo
Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study
GlobeNewswire Inc.
Jan 07, 2025 11:00 AM GMT
Analysis of 447 patients receiving the Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal reaffirms test performanceLOUISVILLE, Colo., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic s
Biodesix Announces Third Quarter 2024 Results and Highlights
GlobeNewswire Inc.
Nov 01, 2024 10:00 AM GMT
Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast Today at 8:30 a.m. ET LOUISVILLE, Colo., Nov. 0